Proactive Investors - Run By Investors For Investors

Invitrocue to discuss its unique Onco-PDO cancer test at Proactive CEO Sessions

The company’s Onco-PDO cancer screening service supports personalised clinical decisions for patients.
New agreement signed focusing on breast cancer models

Invitrocue Ltd’s (ASX:IVQ) Onco-PDO test takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime for a particular type of cancer.

The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a broad panel of chemotherapy drugs to support personalised clinical decisions.

Invitrocue co-founder and executive director Dr. Steven Fang will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Dr. Steven Fang

READ: Invitrocue signs agreement to develop new breast cancer models for its Onco-PDO test

The company recently signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) for the development of new breast cancer models for its Onco-PDO test.

Under the agreement, professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.

The intellectual property (IP) will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any IP developed under the agreement.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Zelda Therapeutics Ltd (ASX:ZLD), Oventus Medical Ltd (ASX:OVN and Infinity Lithium Corporation Ltd (ASX:INF).

View full IVQ profile View Profile

Invitrocue Ltd Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use